


11/12/04

B6/7/11
SEQUENCE



Certificate of Mailing:

PRINTER'S RUSH

The undersigned certifies that this correspondence is being sent via Express Mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 10th day of November, 2004.

(s)

Linda S. Evans
Linda S. Evans

Express Mail Label No.:

EV291407755US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Darrow et al.

Atty Docket: ORT-1566

Serial No.: 10/040,655

Art Unit: 1652

Filed: January 7, 2002

Examiner: William W. Moore

For: Cleaning Compositions Containing
Human Serine Protease T

Confirmation No.: 3674

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Issue Branch

RESPONSE TO EXAMINER'S REQUEST FOR SUBSTITUTE SEQUENCE LISTING

Sir:

The accompanying substitute Sequence Listing is being filed in response to a request by Examiner Moore made in a telephonic message to the undersigned on November 4, 2004 regarding the above-captioned allowed application, which is being prepared for issuance (the issue fee having been transmitted on October 25, 2004).

Examiner Moore informed the undersigned that the sequence information set forth in the computer readable form (CRF) did not correspond with the paper version of the

Sequence Listing as filed with the present application on January 7, 2002. In particular, the Examiner informed the undersigned that the paper version of the Sequence Listing as filed is apparently incomplete insofar as it contains only nine sequences, whereas the CRF contains two additional sequences, as reflected in the parent U.S. application, Serial No. 09/386,653, now U.S. Patent No. 6,458,564.

Upon review, it is apparent that the paper version of the Sequence Listing of record in the present divisional application indeed fails to include SEQ.ID.NO.:10 and SEQ.ID.NO.:11. The undersigned appreciates the USPTO's detection of this error.


To correct the error, which the undersigned believes was made in good faith without deceptive intent, Applicant is providing herewith a substitute Sequence Listing, which contains all eleven sequences. The addition of SEQ.ID.NO.:10 and SEQ.ID.NO.:11 in the accompanying substitute Sequence Listing is supported not only by the CRF as originally filed, but also by Table 1 of the specification, which provides the amino acid sequences corresponding to SEQ. ID. NO.: 10 and SEQ.ID.NO.: 11. Thus, the substitute Sequence Listing does not include new matter.

Pursuant to 37 C.F.R. §1.825(b), a diskette containing a substitute CRF is also enclosed. The undersigned states that the enclosed CRF is the same as the substitute Sequence Listing in paper form submitted herewith. Since the substitute Sequence Listing corrects the above-noted informalities and includes no new matter, Applicant respectfully requests its entry so that the patent issuing from this application will list complete sequence information.

It is believed that no fee is due in connection with the submission of this paper. If it is determined that any fee is due, however, please charge all necessary fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date: November 10, 2004



Linda S. Evans
Reg. No. 33,873

LSE/MDR

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406